Johnson & Johnson reported that its experimental FcRn blocker, nipocalimab, met the primary endpoint in the JASMINE Phase 2b study of 228 systemic lupus erythematosus patients, with a statistically significant reduction in disease activity scores at 24 weeks versus placebo (p<0.01). Key secondary endpoints—including reduction in flare rates and corticosteroid tapering—were also achieved, with 65% of nipocalimab‐treated subjects sustaining a ≥4-point decrease in SLEDAI-2K score compared with 32% on placebo. The safety profile was favorable, with most adverse events classified as mild to moderate; serious events occurred in 4% of treated patients versus 6% in the control arm. Johnson & Johnson plans to initiate global Phase 3 trials in H2 2026, positioning nipocalimab as a potential first-in-class therapy in a market where current annual sales exceed $5 billion and competitors include UCB/Biogen’s rozanolixizumab and Adicet’s ACTR707.

On January 6, 2026, Johnson & Johnson submitted a Type II variation application to the European Medicines Agency seeking approval for the combination of teclistamab and daratumumab subcutaneous in relapsed/refractory multiple myeloma after one prior line of therapy. The application is supported by data from the Phase 3 MajesTEC-3 study of 587 patients, which showed an 83.4% reduction in risk of progression or death at three years (hazard ratio 0.17; 95% CI, 0.12–0.23; p<0.0001). More than 90% of patients who were progression-free at six months remained so at 36 months. Grade 3/4 treatment-emergent adverse events occurred at similar rates in both arms (95.1% vs. 96.6%), with cytopenias and infections most common. The submission follows Breakthrough Therapy Designation granted by the FDA in late 2025 and underscores Johnson & Johnson’s strategy to deploy off-the-shelf immunotherapy earlier in the myeloma treatment paradigm.

Investors evaluating Johnson & Johnson value its diversified portfolio spanning pharmaceuticals, medical devices and consumer health. In 2025, Innovative Medicine division revenues grew 9% year-over-year to $55 billion, driven by oncology, immunology and cardiovascular franchises, while MedTech sales rose 7% to $30 billion, led by robotic surgery and orthopaedic implants. By comparison, oncology-focused peers have delivered higher single-year sales growth (12%–15%) but with greater revenue concentration. Johnson & Johnson’s broad geographic footprint—45% of sales in the U.S., 30% in Europe and 25% in emerging markets—provides resilience against regional reimbursement shifts. The company’s pipeline of more than 100 active clinical programs and a $16 billion R&D budget for 2026 reinforce its capacity for stable, long-term earnings expansion.